Table 1 Characteristics of Study Population
From: Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance
| Â | Standard dose group (n = 80) | High dose group (n = 18) | p-value |
|---|---|---|---|
Age | 56 ± 14 | 67 ± 10 | 0.001 |
Male | 53 (66%) | 13 (72%) | 0.63 |
Height | 172 ± 10 | 171 ± 11 | 0.89 |
Weight | 84 ± 16 | 84 ± 19 | 0.98 |
BSA | 1.99 ± 0.21 | 1.99 ± 0.28 | 0.95 |
Caffeine < 12 hours prior to scan | 4 (5%) | 2 (11%) | 0.31 |
Hypertension | 34 (43%) | 7 (39%) | 0.78 |
Diabetes | 4 (5%) | 4 (22%) | 0.036 |
Hyperlipidaemia | 35 (44%) | 9 (50%) | 0.63 |
Family history of CAD | 12 (15%) | 2 (11%) | 1.00 |
Current Smoking | 5 (6%) | 0 (0%) | 0.58 |
Coronary angiography | 42 (53%) | 11 (61%) | 0.54 |
Single vessel CAD | 14 (33%) | 6 (38%) | 0.49 |
Multi-vessel CAD | 2 (5%) | 4 (22%) | 0.013 |
End-diastolic volume (ml) | 157 ± 46 | 183 ± 61 | 0.10 |
End-systolic volume (ml) | 59 ± 38 | 99 ± 62 | 0.018 |
Ejection fraction (%) | 65 ± 13 | 52 ± 19 | 0.007 |
Mass index (gr/m2) | 71 ± 21 | 72 ± 18 | 0.79 |
B-blockers | 22 (28%) | 6 (33%) | 0.62 |
Ca-inhibitors | 13 (16%) | 4 (22%) | 0.51 |
ACE-inhibitors | 32 (40%) | 9 (50%) | 0.44 |
Statins | 32 (40%) | 9 (50%) | 0.44 |
Aspirin | 22 (28%) | 8 (44%) | 0.16 |